AC Immune Stock Price, News & Analysis

AC Immune SA (Nasdaq: ACIU) hosted a webinar featuring Dr. Cynthia A. Lemere discussing the potential of vaccines in treating Alzheimer's and Parkinson's diseases. The session highlighted their precision medicine approach, focusing on three clinical-stage vaccines targeting Tau, Abeta, and α-synuclein. Vaccines are positioned to provide long-lasting immunity and cost-effective treatment options. The company’s pipeline includes ACI-35.030, ACI-24.060, and ACI-7104, with expected clinical data disclosures in 2022, showcasing their commitment to combating neurodegenerative diseases.

AC Immune SA (Nasdaq: ACIU) will host a KOL webinar on August 24, 2022, at 10:00 AM ET, focusing on innovative vaccination strategies for Alzheimer's and Parkinson's diseases. The event will feature Dr. Cynthia A. Lemere from Brigham & Women's Hospital, discussing the immunotherapy landscape and biomarker selection. AC Immune's management will present their precision medicine approach and pipeline. A live Q&A session will follow the presentation. Registration is available online, with a replay planned for later viewing on the company's website.

AC Immune SA (Nasdaq: ACIU) announced the presentation of findings from the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial at the Alzheimer’s Association International Conference. Crenezumab, the anti-amyloid beta antibody tested, was safe with no ARIA-E cases observed. Numerical differences favoring crenezumab over placebo were noted, but none reached statistical significance. The study's limitations included lower statistical power due to the population's demographics. All mutation carriers will continue receiving crenezumab as data is further analyzed.

AC Immune SA (NASDAQ: ACIU) announced significant clinical advancements and financial updates. The company has delivered three clinical readouts in 2022 and aims for four more by year-end. The first patient has been dosed in the Phase 1b/2 trial of its anti-Abeta vaccine ACI-24.060 targeting Alzheimer's and Down syndrome. Financially, AC Immune holds CHF 154.1 million, ensuring operations through Q1 2024. However, a net loss of CHF 19.6 million was reported for Q2 2022, slightly higher than the previous year's loss.

AC Immune SA (NASDAQ: ACIU) has announced its participation in the Alzheimer’s Association International Conference (AAIC) from July 31 to August 4, 2022, in San Diego. The company will present 10 findings, including new Phase 2 results for the Tau PET tracer PI-2620 and an innovative clinical trial design for ACI-24.060 aimed at Alzheimer's and Down syndrome patients. CEO Andrea Pfeifer emphasized the significance of these results in shifting treatment paradigms for neurodegenerative diseases, highlighting the collaboration with partners like Genentech.

AC Immune SA (NASDAQ: ACIU) held its Annual General Meeting in June 2022, where shareholders re-elected the Board of Directors. Douglas Williams continues as Chairman. The company reported progress in its pipeline, including interim Phase 1b/2a data for the anti-pTau vaccine ACI-35.030 and clinical proof-of-concept for an alpha-synuclein PET tracer. They remain on track for four additional clinical data readouts in 2022 and have sufficient cash for operations into 2024.

AC Immune SA (NASDAQ: ACIU) announced results from its Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial. The investigational drug, crenezumab, did not statistically significantly slow cognitive decline in patients with a specific genetic mutation linked to early-onset Alzheimer’s. Although numerical advantages over placebo were noted, they lack statistical significance. The trial, involving 252 participants, reported no new safety issues. Initial data will be shared at the Alzheimer's Association International Conference on August 2, 2022.

AC Immune announced participation in the 2022 Jefferies Healthcare Conference from June 8-10, 2022, in New York. CEO Andrea Pfeifer will discuss the company's progress in neurodegenerative disease treatments during a fireside chat on June 9 at 8:00 am EDT. The company aims to shift the treatment paradigm towards early diagnosis and disease prevention. Key milestones include the reporting of Phase 2 results for crenezumab in an Alzheimer's prevention trial, expected soon. AC Immune is focused on advancing precision medicine through its innovative therapeutic and diagnostic pipeline.

AC Immune (NASDAQ: ACIU) announced that CEO Dr. Andrea Pfeifer will receive the Aenne Burda Award for Creative Leadership during the DLD Conference in Munich, May 20-22, 2022. This award recognizes her pioneering work in neurodegenerative diseases, including Alzheimer’s and Parkinson’s. Under her leadership since 2003, AC Immune has developed a promising pipeline of diagnostics and treatments, positioning the company as a leader in precision medicine. The award highlights the urgency of addressing global challenges posed by these diseases.